According to the study’s author Emily Jane Woo, MD, adverse event reports have resulted in safety notifications, label changes and publications covering the safety of biologics. Risks include airway compromise, fatal air embolism and infections following various techniques and procedures.
“In light of the rapid development of new biologics, postmarketng surveillance is imperative for ensuring that these products are as safe as possible,” Dr. Woo concluded. “By reporting adverse events, surgeons and other healthcare professionals play a key role in improving and refining our understanding of the safety of biologics.”
More Articles on Spine Surgeons:
Data-Driven Healthcare: Where Spine Surgeons Fit In
Raising & Maintaining Staff Engagement: 6 Spine Surgeon Leaders Discuss
18 Recent Spine Surgery Studies and Findings
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.